Platinum compounds are crucial chemotherapy drugs for children with solid tumor, and the ototoxicity is one of the dose-limiting toxicities. Platinum-induced hearing loss is detrimental to language learning and social development especially for children. Several clinical trials of drugs against platinum-based ototoxicity have been carried out, the results prompted that sodium thiosulfate, amifostine and N-acetylcysteine potentially reduce the occurrence risk of hearing loss. Without affecting the therapeutic effect, preventive use of antagonists on platinum-based ototoxicity will improve the life quality and treatment compliance of pediatric patients with tumor.Progress on prophylactic medicine against platinum-based ototoxicity in children with solid tumor.